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Abstract
Motivation: Understanding the relationship between the sequence, structure, binding energy,
binding kinetics and binding thermodynamics of protein–protein interactions is crucial to under-
standing cellular signaling, the assembly and regulation of molecular complexes, the mechanisms
through which mutations lead to disease, and protein engineering.
Results: We present SKEMPI 2.0, a major update to our database of binding free energy changes
upon mutation for structurally resolved protein–protein interactions. This version now contains
manually curated binding data for 7085 mutations, an increase of 133%, including changes in kinet-
ics for 1844 mutations, enthalpy and entropy changes for 443 mutations, and 440 mutations, which
abolish detectable binding.
Availability and implementation: The database is available as supplementary data and at https://
life.bsc.es/pid/skempi2/.
Contact: moal@ebi.ac.uk
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Protein–protein interactions are central to almost all biological proc-
esses, from cellular signal transduction and the assembly of meso-
scopic structures such as myofilaments, to viral adhesion and the
immune response. Consequently the effects of changes in protein
sequence on the structure, thermodynamics and kinetics of protein–
protein interactions has wide implications for constraining the per-
missible substitutions that accrue over the course of evolution, and
for understanding the molecular etiology of disease. Methods which
measure, predict or optimize these changes have applications in
designing de novo interactions (Fleishman et al., 2011), enhancing
the specificity and affinity of biological therapeutics (e.g. Arkadash
et al., 2017), designing combinatorial protein libraries (e.g. Guntas
et al., 2010), uncovering the effects of pathological mutations (e.g.
Tidow et al., 2006), locating druggable binding sites (e.g. Stevers
et al., 2017) and binding hotspots for drug design (Guo et al.,
2014), altering binding kinetics (Cohen-Khait and Schreiber, 2016;
Rosenfeld et al., 2017), protein–protein docking (e.g. Epa et al.,
2013), and characterizing transition states (e.g. Wu et al., 2002),
binding pathways (Plattner et al., 2017), and sequence-affinity land-
scapes (Aizner et al., 2014).
SKEMPI is a manually curated database of mutations in structur-
ally characterized protein–protein interactions and the effect of
those mutations on binding affinity and other parameters (Moal and
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Fernandez-Recio, 2012). The first release has been used as a basis
for many further studies, including the development of energy func-
tions (Moal and Fernandez-Recio, 2013; Moal et al., 2015b) which
were subsequently implemented in the CCharPPI web server for
characterizing protein–protein interactions (Moal et al., 2015a), as
well as being used for ranking docked poses (Barradas-Bautista
et al., 2017; Moal et al., 2013; Moal et al., 2017; Pfeiffenberger
et al., 2017). SKEMPI has also been used to study human disease
(Das et al., 2014; Peng and Alexov, 2016; Petukh et al., 2015a),
assessing the role of dynamics on binding (Sumbul et al., 2015),
exploring the conservation of binding regions (Hu et al., 2016), eval-
uating experimental affinity measurement methods (Geng et al.,
2016), as well serving as a data source for models which predict dis-
sociation rate changes upon mutation (Agius et al., 2013), patho-
logical mutations (Gossage et al., 2014), hotspot residues (e.g.
Hwang et al., 2014; Liu et al., 2015; Melo et al., 2016; Simoes
et al., 2017) and changes in binding energy (e.g. Barlow et al., 2018;
Berliner et al., 2014; Dehouck et al., 2013; Dourado and Flores,
2014; Lai et al., 2017; Li et al., 2016; Moretti et al., 2013; Pallara
et al., 2013; Pantazes et al., 2015; Petukh et al., 2015b; Pires et al.,
2014; Xiong et al., 2017; Yan et al., 2017; Zhao et al., 2014).
Here we present a major update to the benchmark in terms of
the number of mutations in the database and the number of different
systems included (Table 1). We now also include details of the ex-
perimental method for all entries, based on the categories of Geng
et al., 2016, as well as mutations which abolished detectable binding
or for which only an upper or lower affinity limit could be ascer-
tained for the wild-type or mutant.
2 Materials and methods
2.1 Data sources
Just over two fifths of the data come from the previous version of
SKEMPI (Moal and Fernandez-Recio, 2012), comprised mostly of
data found in literature sources which came to the authors’ atten-
tion, in some cases during the data collection for the structural affin-
ity benchmark (Kastritis et al., 2011) and following references
therein. Some entries in SKEMPI 1.1 were found by checking the
references in the ASEdb (Thorn and Bogan, 2001) and PINT
(Kumar and Gromiha, 2006) databases, although not all the data
passed the checks required for inclusion (see Section 2.2). Similarly,
most of the new data in SKEMPI 2.0 was found by searching the lit-
erature, partly in tandem with the literature search for the more re-
cent structural affinity benchmark (Vreven et al., 2015). During
data collection three other relevant databases were published:
ABbind (Sirin et al., 2016), PROXiMATE (Jemimah et al., 2017)
and dbMPIKT (Liu et al., 2017). Their references were checked if
they were not already included. Data from these sources comprise
4%, 3% and 6% of SKEMPI 2.0 respectively. As with ASEdb and
PINT, none of the data were directly copied into SKEMPI.
Moreover, the cited papers were read and data entered using the
same checks and procedures as other entries.
2.2 Data collection
Each entry was found in the literature and manually vetted. To en-
sure quality, a number of stringent checks were applied. Firstly, we
ensured that the structure and the paper reporting the affinities refer
to the same protein in the same species, and that structural and af-
finity data matched in terms of cofactors, ancillary chains and post-
translational modifications. For instance, we distinguish between
RasGTP and RasGppNHp, as the nucleotide modulates the affinity
of Ras with its effectors. Where the full-length protein was not used,
we checked to ensure that the fragment in the crystal structure
matched that for which affinities are reported.
Once the checks are passed, the data is collected, including the
PDB file, the chains of the interacting subunits, the mutation, the
wild-type and mutant affinities (KD, M), the reference, the names of
the proteins, the temperature at which the experiment is performed
(T, K), the experimental method used (an extension of the category
scheme of Geng et al., 2016), notes on the entry and, when avail-
able, the association rate (kon; M
1s1), dissociation rate (koff ; s1),
enthalpy (DH; kcal:mol1) and entropy (DS; cal:mol1:K1). For
cases where multiple PDB entries are available, the higher resolution
structure is chosen. Where affinities or kinetic or thermodynamic
parameters are reported in different units, these are converted to the
units specified above. In some cases, when not reported directly, KD,
kon; koff ; DH and DS were calculated using the relationships DG
¼ DH  TDS ¼ RTlnðKDÞ and KD ¼ 1=KA ¼ koff=kon. To ensure
consistency, the residue numbering in SKEMPI is the same as that
reported in the PDB file. Thus, the numbering is often shifted or
altered compared to that in the cited paper such that, for instance, if
a crystal structure of an antibody is reported in the Kabat numbering
scheme but the mutation data is not, then the mutation data is con-
verted before entry into SKEMPI. For all entries it is the case that
the affinity reported in the “wild-type” column corresponds to that
of the PDB file, and the affinity in the “mutant” column is that after
applying the specified mutation to the protein in the PDB file. Thus,
where there are cases in which the PDB reports a mutant form and
the entry corresponds to the reverse mutation back to the wild-type,
the affinity of the former appears in the “wild-type” column and the
latter in the “mutant” column. Such cases are noted in the database.
In addition to checking new entries, we reappraised the papers
cited in SKEMPI 1.1 to collect data that were not collected previous-
ly, specifically to find mutants which abolish binding and to classify
the experimental method used when not already included in the sub-
set of SKEMPI covered in Geng et al., 2016. It is worth noting that
often an author’s decision to report an interaction of affinity below
the detection threshold as either non-binding, or as less affine than
the weakest affinity presented in the paper, is arbitrary. Thus, those
wishing to use the non-binding data as an inequality on the affinity
may do so. We also corrected entries for five wild-type and four mu-
tant affinities identified by Geng et al., 2016.
2.3 Post-processing and annotation
In addition to the above data, SKEMPI 2.0 also provides data on the
location of the mutated residues, the homology between interactions
in the dataset, and processed PDB files, which can be easily parsed.
Residue location: Each mutated residue is classified according to
the scheme proposed by Levy (2010); residues at the interface are
classified as support (mostly buried when unbound and entirely
Table 1. Comparison with previous version
SKEMPI 1.1 SKEMPI 2.0
Entries 3047 7085
Unique entries 2792 6187
kon and koff 713 1844
DH and DS 127 443
Inequalities/no binding 0 440
Number of interactions 87 237
Number of PDB entries 158 345
Number of papers cited 66 295
2 J.Jankauskait _e et al.
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buried upon binding), core (mostly solvent exposed when unbound
but buried upon binding) and rim (partly buried upon binding),
while residues away from the binding site are classified as interior or
surface. Solvent exposed surface area was calculated using CCP4
(Winn et al., 2011).
Processed PDB files: The PDB files for the interactions, as down-
loaded from the Protein Data Bank (Berman et al., 2000), often con-
tain multiple copies of the interacting proteins in the unit cell or
other chains irrelevant to the interaction. In one instance, the bind-
ing of dimeric myostatin to follistatin-like 3, the myostatin dimer
must be created by tessellating the unit cell. Further, some PDB files
contain features that are not readily parsed by some software, such
as residue insertion codes or negative residue numbers. To help users
we provide “cleaned” PDB files which contain only the chains of
interest, renumbered from one, as well as waters and other mole-
cules with a non-hydrogen atom within 5 A˚ of a non-hydrogen atom
of any of the chains of interest. Consequently, each mutation is
reported with both PDB numbering and renumbered.
Defining homologous interactions: Each entry also specifies
which other entries are mutations to homologous interactions. Two
interactions are deemed homologous if they have a shared binding
partner or homologous binding partner and at least 70% of the cor-
responding interface residues are common to both interactions. We
determine the homology between proteins using the GAP4 program
(Huang and Brutlag, 2007), and define homologous proteins as
those with a similarity score greater than 50 and at least 30% se-
quence identity. Interface residues are defined as those with a non-
hydrogen atom within 10 A˚ of a non-hydrogen atom on the binding
partner. Interactions falling within manually assigned clusters of
homologous interactions are designated as pMHC/TCR, antibody/
antigen or protease/inhibitor. While the names of these clusters have
been chosen to reflect the predominant function of their constituent
interactions, they reflect the homologies within the dataset and are
not functional assignments. Thus, for instance, some nanobodies are
classified as antibodies as they bind to the same site as cetuximab,
14.3.d is classified as TCR, even though it is only the b chain, and
its binding partner, enterotoxin C3, is classified as a pMHC.
3 Results and discussion
3.1 Diversity, bias and interrelationships within SKEMPI
In total 7085 entries were collected, summarized in Table 1 and
Figure 1A. These data were derived from the literature and conse-
quently, while encompassing a broad range of residues, proteins,
interactions and systems, are biased toward the interests and capa-
bilities of the research community. These biases are evident in the
composition of the database according to parameters shown in
Figure 1. The DDG values span a large range, but mostly fall within
–3 to 7 kcal:mol1 (Fig. 1B), for both biophysical and technical rea-
sons (see Section 3.3). Almost three quarters of the data correspond
to single point mutations, and more than half of those are mutations
to alanine (Fig. 1C). Charge swap mutations and mutations between
aromatic residues are also over-represented. Most single point muta-
tions are located at the binding site, and most of those are at the
core of the interface. Similarly, most double mutations are both in
the binding site, and most of those are both in the core. By far the
most popular methods for measuring binding affinity were surface
plasmon resonance and spectroscopic methods such as fluorescence.
Large biases toward specific interactions and classes of interaction
are also present, such as early studies into protease inhibition and
immunological interactions such as antibody-antigen complexes, the
recognition of peptides presented on cell surfaces by T-cell receptors,
cytokine signaling and the complement system. Indeed, almost half
of the data corresponds to protease-inhibitor, antibody-antigen and
pMHC/TCR interactions alone. While many interactions within
these classes share common binding sites or homologous binding
sites (Fig. 2), there are also connections between these groups, for in-
stance via inhibitory antibodies which bind to a protease active site,
or due to common binding regions of proteins in the immunoglobu-
lin superfamily, such as antibodies, TCRs, MHCs and b-2 microglo-
bulin. In addition, present in the data are smaller clusters of shared
and homologous interactions, such as the Ras-effector cluster. These
relationships are noted in the database and may be useful for avoid-
ing overfitting when developing models or for validation and esti-
mating generalization error, as described previously (Moal and
Fernandez-Recio, 2012).
The entries also vary in the degree of structural order. While
most correspond to interactions between folded domains, the data-
base contains entries in which structuring occurs upon binding, such
as protein–peptide interactions and, in the extreme case, the ACTR/
NCBD interaction in which both binding partners become ordered
upon binding (Jemth et al., 2014). Indeed, the requirements of hav-
ing a structure in order to be included in the dataset, ipso facto
biases the data, and means that there is no representation of “fuzzy”
complexes in which a diffuse structural ensemble in the bound state
prevents the formation of a resolvable crystal.
Another source of variation is the origins of the interacting pro-
teins. While entries range from viral and bacterial to the higher
eukaryotes, biases are evident in the over-representation of model
organisms including humans. With the exception of the pMHC-
TCR, antibody-antigen and protease-inhibitor classes, most of the
interactions are endogenous. Nevertheless, the set also includes ex-
ogenous interactions ranging from those between proteins from dif-
ferent individuals within the same species, namely the sex fusion
proteins Juno and Izumo1 from human sperm and egg respectively
(Aydin et al., 2016), to host-pathogen interactions such as adeno-
virus and coronavirus interactions with human receptors during
viral entry (Howitt et al., 2003; Seiradake et al., 2006), to the inhib-
ition of acetylcholinesterase by the snake venom neurotoxin fascicu-
lin (Aizner et al., 2014). For the pMHC-TCR interactions, there are
a variety of presented antigens, including exogenous viral peptides
and gluten, as well as endogenous autoimmune and cancer peptides.
The antibody interactions include pathogen antibodies, as well as
antibodies raised and optimized to target extracellular therapeutic
targets. The protease interactions are mostly exogenous, arising
from their inherent cross-reactivity due to the convergent evolution
of their canonical inhibitory loop.
3.2 Notable studies comprising SKEMPI 2.0
The investigations from which SKEMPI data is derived are diverse,
spanning many biological processes and reported in 295 publica-
tions including systematic scans, alanine and homolog scanning, de-
sign studies including computational design and designs derived
from phage display, double mutant cycle studies, antibody engineer-
ing, biologic drug design and the evaluation of pathological muta-
tions. The largest contribution comes from the group of the late
Michael Laskowski Jr., a systematic study of all possible mutations
at selected sites in the turkey ovomucoid third domain and its inhibi-
tory interactions with four proteases (Lu et al., 2001), as well as
studies of interactions of the same domain in other bird species and
the design of ultra-high affinity broad-spectrum inhibitors.
Substantial data also come from investigations into the inhibitory
SKEMPI2 3
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interactions of class A b-lactamases from the groups of Gideon
Schreiber (e.g. Reichmann et al., 2007) and Timothy Palzkill (e.g.
Brown et al., 2013), as well as cytokine receptor interactions, in par-
ticular studies of type I interferons also from the Schreiber group
(e.g. Roisman et al., 2001) and that of K. Christopher Garcia
(Thomas et al., 2011), but also the study of the GM-CSF/GMRa
interaction from the group of Michael W. Parker (Broughton et al.,
2016). Other prominent sources of data are studies into hormone re-
ceptor interactions, in particular the human growth hormone recep-
tor from the group of Jim Wells (e.g. Cunningham and Wells, 1991)
and the prolactin receptor from the group of Michael E. Hodsdon
(Kulkarni et al., 2010), as well as studies into antigen recognition
including the combined computational and experimental design
study to enhance affinity of the AQC2 antibody to integrin a-1 from
the group of Herman Van Vlijmen (Clark et al., 2006), the dissec-
tion of the interactions of broadly neutralizing antibodies targeting
HIV gp120 (Clark et al., 2017) from the group of Richard A.
Friesner, and various investigations from the group of Roy A.
Mariuzza (e.g. Dall’Acqua et al., 1998). Also notable is the alanine
scanning of the urokinase-type plasminogen activator and its recep-
tor from the group of Michael Ploug (Gardsvoll et al., 2006), studies
of Ras effector interactions from the group of Christian Herrmann
(e.g. Kiel et al., 2004), investigations of pMHC/TCR interactions
from the group of Brian Baker (e.g. Piepenbrink et al., 2013), and
investigations into the cognate and non-cognate recognition of
Escherichia coli colicin DNase bacteriotoxins by their immunity
proteins from the group of Colin Kleanthous (e.g. Li et al., 1997).
3.3 Range and error
Range: The changes in binding free energy upon mutation range
from –12.4 to 12.4 kcal:mol1, as in SKEMPI 1.1, with D log 10kon
ranging from –3.6 to 2.4, D log 10koff ranging from –6.0 to 6.8, DDH
W
ild
-ty
pe
 a
m
in
o 
ac
id
Mutant amino acid
A
B C
Fig. 1. An overview of SKEMPI 2.0. (A) Mutations partitioned according to their origin, the number of altered residues, location within the complex, by the avail-
ability of additional kinetic and thermodynamic data, according to the experimental method used, and by category. (B) Distribution of DDG. (C) Source and target
amino acids for single point mutations
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Fig. 2. Overview of the interactions in SKEMPI. Nodes indicate proteins, scaled by the number of mutations of that protein and coloured according to category.
Edges show direct interactions, as well as relationships between proteins that share a common or homologous binding site
SKEMPI2 5
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ranging from –18.3 to 26.5 kcal:mol1, and DDS ranging from –61
to 80 cal:mol1:K1. Around 60 mutants are very destabilizing,
reducing binding energy by 8 kcal:mol1 or more. These are all in
enzyme/inhibitor complexes such as the inhibition of acetylcholin-
esterase by the snake venom fasciculin, or the inhibition of enzymes
which would be detrimental should they unbind and become active
in the wrong location, such as nucleases (barnase/barstar, colicin E9
DNase/Im9, RNase A/angiogenin) and proteases (such as trypsin/
BPTI). These interactions tend to be around picomolar affinity and
are at the upper limit of what can be detected, due to the time
required to reach equilibrium and the low concentrations required
by the mass action law to probe informative regions of the binding
curve. These very destabilizing mutations reduce affinity into the
micromolar range, near the lower limit of what can be quantified
using standard methods. As a consequence of both mutant and wild-
type affinities being near detection thresholds, errors in these entries
are typically large. Further, while some mutations may cause
changes in affinity larger than seven orders of magnitude, the ab-
sence of affinities for such mutations in the benchmark can be
explained by the fact that such mutations would involve affinities
beyond the upper or lower limit. Indeed, there are new entries in
which single or double substitutions reduce binding from tens of
picomolar to having no detectable binding. For many of the highly
destabilizing mutations a crystal structure for the mutant has also
been solved, and the 30 most stabilizing mutations in the database
(DDG ¡ –5 kcal:mol1) consist of the reverse mutation applied to
these structures. These are mostly single or double mutants, but in-
clude mutations to up to 27 residues of the non-cognate Colicin E2/
Im9 complex, which move it toward the cognate E9/Im9 in sequence
space (Li et al., 1997).
Errors: Standard errors in KD are typically reported in the order
of 50%, around 0.25 kcal:mol1. These estimates are derived by re-
peat measurements using the same equipment, environment and
protocol, and thus do not include errors arising from systematic
bias. Such biases can, however, be estimated from pairs of entries in
which the same mutation is evaluated by different groups or using
different techniques. For 84% of 1741 such pairs, both entries give a
DDG value within 1 kcal:mol1 of each other. For 704 pairs for
which kon is available for both, 80% have D log 10ðkonÞ within 0.5 of
each other. For 702 pairs for which koff is available, 83% have
D log 10ðkoffÞ within 0.5. For the 62 pair with both DDH and
DDS values, 61% have DDH within 3.0 kcal:mol1 of each other
and 58% have DDS within 10 cal:mol1:K1 of each other.
3.4 Mutant cycles
Within SKEMPI, some entries can be combined to construct mutant
cycles, which quantify the interactions between residues, the depend-
ence of these interactions on other residues, and other higher order
effects. The most common instances are double mutant cycles, where
affinities are available for the wild type, A, B and AB mutations, of
which there are 610 examples. Of these, 53 involve at least one mu-
tant for which binding was not observed, or only an inequality is
available, and 235 involve mutations reported in the same reference,
and thus the affinities are likely to have been measured using the
same technique and conditions. A further 218 double mutant cycles
can be constructed in the background of a third mutation (i.e. C, AC,
BC and ABC mutations are available), of which 209 are not com-
posed of non-binding mutations or mutations with inequalities, and
131 involve affinities coming from the same reference. Of the 766
double mutant cycles containing neither inequalities nor non-binding
mutants, a number of parameters can be calculated, including
DDGab!Ab; DDGab!aB and DDGab!AB, the binding free energy
change of both single and the double mutation respectively, as well as
DDGaB!AB and DDGAb!AB, the energy of a single mutation within
the context of the other mutation, and DDGint ¼ DDGaB!AB
– DDGab!Ab ¼ DDGAb!AB  DDGab!aB, the interaction energy of
the two mutations (Horovitz and Fersht, 1990). From these, it can be
deduced that 345 are additive (DDGint < 0:5kcal:mol
1). Of the
non-additive cycles, 293 exhibit tighter binding in the double mutant
than the sum of the single mutants (positive epistasis), of which six
result in even tighter binding than individual effects of two single
mutations that strengthen the interaction (synergistic positive), while
273 correspond to double mutants which reduce binding by less than
the sum of two single mutants which reduce binding (antagonistic
positive). Similarly, 128 cycles have double mutants exhibiting
weaker binding than the sum of the two single mutants (negative
epistasis), of which 58 contain two destabilizing single mutations
(synergistic negative) and 26 contain two stabilizing single mutations
(antagonistic negative). The range of DDGint values rarely fall outside
of the –5 to 3 kcal:mol1 range. Of the 421 non-additive cycles, 151
show noticeable sign epistasis, in which the sign of the effect of either
the A or B mutation flips depending on the presence or absence
of the background mutation (i.e. for the A mutation, jDDGab!Abj
> 0:2 kcal:mol1 and jDDGaB!ABj > 0:2 kcal:mol1 and
jDDGab!Ab  DDGaB!ABj > 0:4 kcal:mol1). Of these, 38 corres-
pond to mutations, which destabilize the complex in the presence of
the background mutation, but stabilize in its absence (destabilizing
sign epistasis), while 113 correspond to mutations, which stabilize
the complex in the mutant background but otherwise destabilize the
complex (stabilizing sign epistasis). Only eight cycles exhibit the
more extreme reciprocal sign epistasis, which in six cases are where
both single mutations are stabilizing (< 0:2 kcal:mol1), but the
double mutant is destabilizing (>0.2 kcal:mol1), and the remaining
two correspond to two destabilizing mutations (>0.2 kcal:mol1) for
which the double mutation is stabilizing (< 0:2 kcal:mol1). The
types of substitutions that can give rise to extreme effects such as sta-
bilizing reciprocal sign epistasis can be illustrated with the Mlc-
IIBGlc interaction in E. coli (Nam et al., 2008), in which the removal
of the F136 side-chain of MlC creates a large cavity at the binding
interface, the addition of a phenylalanine at the A451 position of
IIBGlc creates a large clash, however the double mutation creates an
interaction that is even more stable than the wild-type by creating an
anchor residue across the binding interface in which the cavity in
MlC is filled by the new side-chain of IIB.
Higher order interaction terms can be garnered from higher
cycles, such as triple mutant cubes, constructed from the energies of
the wild-type, three single mutants, three corresponding double
mutants and the triple mutant (Horovitz and Fersht, 1990). In
SKEMPI, 45 triple mutant cubes can be made, with 10 coming from
the same reference. For these, third order interaction energies fall
within the –1 to 1 kcal:mol1 range. For fourth order interactions,
constructed from energies of the wild-type, four single mutants, six
double mutants, four triple mutants and the quadruple mutant, 14
examples exist within SKEMPI. However, care should be taken in
ascribing meaning to fourth order residue coupling energies due to
the accumulations of errors, which in these cases are exacerbated by
the affinities having been reported in different publications. No fifth
or higher order interactions are present.
3.5 The SKEMPI website
The database is accessible online at https://life.bsc.es/pid/skempi2/,
where the raw CSV (comma-separated values) file containing all the
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data can be downloaded. The data can also be browsed online,
ordered and searched by any field, such as the experimental method
or the location of the mutation, or searching for a specific protein by
its name or PDB code, and structures may be visualized. Other pages
on the web site offer a summary of the data, an FAQ and help page,
and a page for user contributions, which will be evaluated to appear
in future releases.
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